ABSTRACT
OBJECTIVE@#To evaluate the quality of life (QOL) on patients with multiple myeloma(MM) during maintenance therapy and to explore the related factors important for QOL.@*METHODS@#The demography, clinical and laboratorial data of 66 MM patients during maintenance therapy were collected and explored by using a cross-sectional question naire(EORTC QLQ C30 V 3.0). The statistical analysis was performed using Nowegram normal mode(NM) and reference values(RV) of MM patients which were used as control.@*RESULTS@#In comparison with Nowegran normal mode, the scores of general health status, physical function, role function and social function of patients during maintenance therapy were lower than those of normal mode (61.3, 73.9, 65.4 and 65.2 vs 75.3, 89.9, 83.3 and 85.8 respectively), while the scores of constipation and financial difficulty were higher than those of normal mode(16.7 and 44.4 vs 10.7 and 9.7 respectively) (P<0.05). In comparison with reference values, the scores of general health status, emotional and coguitive functions of patients during maintenance therapy were significantly higher than those of reference values(61.3, 81.7 and 84.3 vs 55.7, 71.3 and 78.1 respectively) (P<0.05). In addition, the maintenance therapy yet decreasd the scores of fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss and constipation of patients, but increased the score of financial difficulty of patients (P<0.05). The age of initial diagnosis, serum LDH level, peripheral neuropathy, high ratio of own expense and underlying diseases were main factors affecting the general health status of patients (P<0.05), while the decrease of Hb level, increase of blood Ca level and accompanied genetic changes negatively influence the QOL (P<0.05), while the high culture level showed positive effect on QOL (P<0.05). The choise of drugs for maintenace (therapy thalidomide and bortezomib) not had significant effect on QOL of patients.@*CONCLUSION@#The maintenance therapy can improve the QOL of MM patients, the age at initial diagnses, serum LDH level, peripheral neuropathy and high ratio of own expence are the main factors affecting the QOL of MM patients.
Subject(s)
Humans , Cross-Sectional Studies , Multiple Myeloma , Therapeutics , Quality of Life , ThalidomideABSTRACT
Anesthesia drugs are closely related to metastasis and recurrence of tumors. In recent years, it is believed that anesthetics have important effects on proliferation, migration of tumor cells. Most studies suggest that opioids, mainly morphine, promote tumor growth and metastasis, while the clinical effects of different anesthetic drugs on different types of tumors and different subtypes of the same tumor are vaied. At present, non⁃opioid anesthesia drugs have potential advantages in postoperative metastasis and recurrence of tumor patients. Compared with opioid drugs, they have broad application prospects. This article reviews the progress of general anesthetics, local anesthetics and non⁃opioid analgesics.
ABSTRACT
Objective Few reports are seen domestically on the effect of tramadol (TMD) on the growth and metastasis of lung cancer cells. This study was to investigate the effect of TMD on the proliferation, apoptosis and cell cycle of human lung adenocarcinoma (LAC) A549 cells.Methods We treated human LAC A549 cells with isotonic physiological saline (control) and TMD at 3 μg/mL (low-dose TMD), 30 μg/mL (medium-dose TMD) and 300 μg/mL (high-dose TMD), respectively.After 48 hours of intervention, we detected the proliferation of the cells by CCK-8 assay, determined their apoptosis by Annexin-V FITC/PI double staining, measured the protein expressions of XIAP, Survivin, Bcl-2, Bax, and Caspase-3 in the cells by Western blot, and examined the cell cycle by FCM.Results Compared with the control group, tramadol treatment significantly reduced the absorbance value of the LAC A549 cells (P<0.05) and elevated the level of their apoptosis in the low-, medium- and high-dose TMD groups ([2.1±0.3]% vs [4.9±0.7]%, [9.4±1.4]% and [19.2±2.4]%, P<0.05), both in a dose-dependent manner. In comparison with the saline control, high-dose TMD group showed markedly down-regulated expressions of Survivin (0.98±0.04 vs 0.31±0.02, P<0.05) and XIAP (0.99±0.02 vs 0.38±0.04, P<0.05) but up-regulated expression of Caspase-3 (0.97±0.03 vs 1.06±0.03, P<0.05) in the LAC A549 cells. The ratio of G0/G1 cells was remarkably decreased while those of S and G2/M cells significantly increased, all in a dose-dependent manner (P<0.05).Conclusion Tramadol can inhibit the proliferation, promote the apoptosis and block the cycle of human LAC A549 cells, which may be associated with its abilities of down-regulating the expressions of Survivin and XIAP and promoting the activation of Caspase-3 in the cells.
ABSTRACT
OBJECTIVE@#To evaluate the therapeutic effect and adverse reactions of the maintenance therapies with Thalidomine or Bortezomib in the patients with newly diagnosed multiple myeloma (MM), so as to provide a reference for clinical treatment.@*METHODS@#A retrospective analysis was conducted to compare the progression-free survival (PFS), overall survival (OS) and adverse reaction rate of 23 MM patients received the maintenance therapies of Bortezomib and of 68 MM patients received maintenance therapy of Thalidomine.@*RESULTS@#The maintenance therapy with Bortezomib could extend the PFS of MM patients as compared with Thalidomine (PFS rate of patients on the maintenance therapy of Bortezomib in 12th, and 24th month was 100%, 88.89%, and that of Thalidomine-treated group was 72.31%, 47.54%). What's more, some specific patients could get better 2-year PFS rate in Bortezomib group than that in Thalidomine group, such as older than 65 years old, after autologous hematopoietic stem cell transplantation(ASCT), having genetic changes, extramedullary lesions, poor renal function, low serum free light chain ratio, high β2-MG, anemia, high LDH, VGPR of induction and consolidation therapy. The OS rate of Bortezomib on 18th, 24th and 30th month was 100%, 88.89%, 80% verus 91.52%,83.63%,72.90% of the group with thalidemide at the same time. As for 2-year OS rate, the Bortezomib group was higher than Thalidomine without statistical differences. However, the patients such as older than 65 years old, poor renal function and with extramedullary lesions, would also get higher 2-year OS rate from Bortezomi. Bortezomib and thalidomide could cause bone marrow suppression, peripheral neuritis and other adverse reactions.@*CONCLUSION@#The efficacy of maintenance therapy with Bortezomib is superior to thalidomide. As a conclusion, bortezomib is a better option for maintenance therapy of MM patient.
Subject(s)
Aged , Humans , Antineoplastic Combined Chemotherapy Protocols , Therapeutic Uses , Boronic Acids , Bortezomib , Disease-Free Survival , Multiple Myeloma , Drug Therapy , Pyrazines , Retrospective Studies , Thalidomide , Transplantation, Autologous , Treatment OutcomeABSTRACT
OBJECTIVE: To study the application of Multi-objective Genetic Algorithm in optimization of micro-extraction technology of Schisandrae Chinensis Fructus. METHODS: Sub-target model of extraction rate, schizandrin and the total lignan was established based on micro-extraction Schisandrae Chinensis Fructus experimental data resulted from uniform design. Applying MOGA, the optimal extracting conditions were explored, and the results were compared with those of Single-objective genetic algorithm. Using SGALAB beta5008 of the Matlab2009a plug-in tool-box, the genetic algorithm optimization was achieved. SPSS13.0 software was used for statistical analysis. RESULTS: The optimal conditions were as follows; microwave power 270 W, ethanol 87%, extraction time 7 min, ethanol amount 1:4.5, grinding degree 70. Under these conditions, the extract rate was 21.40%, Schizandrin recovery was 4.72%, and the total lignan recovery was 10.84%. CONCLUSION: MOGA provides a reasonable pareto ensuring the optimal multi-objective, which provides a reasonable method for extraction of Schisandrae Chinensis Fructus. This method can be applied in the selection of extraction technology of other drugs. Copyright 2012 by the Chinese Pharmaceutical Association.
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the method for preventing the postoperative nausea and vomiting (PONV) after laparoscopic gynecologic surgery.</p><p><b>METHODS</b>One hundred and twenty patients being for laparoscopic gynecologic surgery at I- II grade as American Society of anesthesiologists (ASA) were randomly divided into three groups, 40 cases in each group. Twenty minutes before the operation, the mixture of 2. 5 mg Droperidol (1 mL) and 1 mL 0. 9% sodium chloride solution was injected into the bilateral Neiguan (PC 6) in group I , and an intravenous injection with 1 mL Droperidol was used in group II , while there was no treatment carried out in group Ill'. Twenty four hours after the operation, the frequency and degree of nausea and vomiting were observed and scored according to the criteria standard.</p><p><b>RESULTS</b>The incidence rate of nausea was 10. 0% (4/40) in group I , 57. 5% (23/40) in group II , which was significantly different from 80. 0% (32/40) in group III (P<0. 01, P<0. 05, respectively), while it was lower in group I than in group II (P<0. 01). The incidence rate of vomiting was 7. 5% (3/40) in group I , 52. 5% (21/40) in group II , which was significantly different from 75.0% (30/40) in group III (P<0.01, P<0.05 respectively), while it was lower in group I than in group II (P<0.01). No complication, such as obvious drowsiness, anxiety and extracorticospinal tract reaction, was observed among the three groups.</p><p><b>CONCLUSION</b>Acupoint injection at Neiguan (PC 6) with a small dose of Droperidol can effectively prevent the PONV after laparoscopic gynecologic surgery without other adverse effects.</p>